• 1
    Nalesnik MA. Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 1996; 8: 139148.
  • 2
    Penn I, Hammond W, Brettschneider L, Starzl TE. Malignant lymphomas in transplantation patients. Transplant Proc 1969; 1: 106112.
  • 3
    Tsai DE, Hardy CL, Tomaszewski JE et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long- term follow-up of 42 adult patients. Transplantation 2001; 71: 10761088.DOI: 10.1097/00007890-200104270-00012
  • 4
    Mamzer-Bruneel MF, Lome C, Morelon E et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center. J Clin Oncol 2000; 18: 36223632.
  • 5
    Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86: 33333340.
  • 6
    Milpied N, Vasseur B, Parquet N et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphopoliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11: 113116.DOI: 10.1023/A:1008372814223
  • 7
    Rajakariar R, Bhattacharyya M, Norton A et al. Post transplant T-cell lymphoma: a case series of four patients from a single unit and review of the literature. Am J Transplant 2004; 4: 15341538.DOI: 10.1111/j.1600-6143.2004.00521.x
  • 8
    Armitage JM, Kormos RL, Stuart RS et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant 1991; 10: 877886.
  • 9
    Starzl TE, Nalesnik MA, Porter KA et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583587.DOI: 10.1016/S0140-6736(84)90994-2
  • 10
    Nalesnik MA, Makowka L, Starzl TE. The diagnosis and treatment of posttransplant lymphoproliferative disorders. Curr Probl Surg 1988; 25: 367472.DOI: 10.1016/0011-3840(88)90010-X
  • 11
    George TI, Jeng M, Berquist W, Cherry AM, Link MP, Arber DA. Epstein-Barr virus-associated peripheral T-cell lymphoma and hemophagocytic syndrome arising after liver transplantation: case report and review of the literature. Pediatr Blood Cancer 2005; 44: 17.DOI: 10.1002/pbc.20242
  • 12
    Boehm M, Zhang M, Badea B et al. Synthesis and structure-activity relationship of novel retinoid X receptor-selective retinoids. J Med Chem 1994; 37: 29302941.
  • 13
    Duvic M, Hymes K, Hearld P et al. Bexarotene is effective and safe for treatment of refractory advanced stage cutaneous T cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 24562471.
  • 14
    Esteva F, Glaspy J, Baidas S et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 2003; 21: 9991006.DOI: 10.1200/JCO.2003.05.068